Association Between Preoperative HALP and Immediate Postoperative Outcomes

Sponsor
Chitwan Medical College (Other)
Overall Status
Completed
CT.gov ID
NCT05506748
Collaborator
(none)
22
1
12
1.8

Study Details

Study Description

Brief Summary

Multiple inflammation-based prognostic scores have been developed for the prediction of perioperative morbidity and mortality following pancreaticoduodenectomy (PD). Preoperative "Hemoglobin, Albumin, Lymphocytes and Platelets index (HALP)" is one of the promising inflammatory markers that has emerged as a predictor of postoperative survival. To date, no study has been done with preoperative HALP to predict 30days morbidity and mortality.

Is there any association between Preoperative HALP (hemoglobin, albumin, lymphocyte, and platelet) and 30 days post operative morbidity and mortality in patients undergoing Pancreaticoduodenectomy?

Condition or Disease Intervention/Treatment Phase
  • Other: pantients undergoing pancreaticoduodenectomy

Detailed Description

General Objective:

To assess the association between preoperative HALP and immediate postoperative outcome among patients undergoing PD.

Specific Objectives:
  1. To identify the magnitude of immediate post-operative morbidity and mortality in patients undergoing PD.

  2. To evaluate the descriptive measurement of preoperative Hemoglobin, Albumin, Lymphocytes, Platelets and HALP among patients undergoing PD.

  3. To compare the preoperative HALP with morbidity and mortality among patients undergoing PD.

Operational Definition:
  1. Immediate postoperative time - was taken as 30days following surgery.

  2. Morbidity- was defined by Clavién-Dindo20 grading for the surgical complication and DGE,21 POPF,22 and PPH23 -according to International Study Group of Pancreatic Surgery (ISGPS) grading.

  3. Mortality- survival within 30days.

  4. Level of preoperative HALP- normality test was done via SPSS and data of HALP followed normal Gaussian distribution. So, mean was used for the calculation of cut off value as 35.83. And, patients were divided into low HALP (≤35.83) group and high HALP (>35.83) group respectively

Study Design

Study Type:
Observational
Actual Enrollment :
22 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Association Between Preoperative HALP and Immediate Postoperative Outcomes in Patients Undergoing Pancreaticoduodenectomy
Actual Study Start Date :
Apr 20, 2021
Actual Primary Completion Date :
Apr 20, 2022
Actual Study Completion Date :
Apr 20, 2022

Outcome Measures

Primary Outcome Measures

  1. Morbidity- Clavién-Dindo grading : [30days following the pancreaticoduodenectomy]

    It is graded from grade I to V on the basis of surgical site infection, organ space infection, single or multiple organ failure, and death. Grade I Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic, and radiological interventions Grade II Requires pharmacological treatment, blood transfusions, or total parenteral nutrition Grade III Requires surgical, endoscopic, or radiological intervention IIIa Not under general anesthesia IIIb Under general anesthesia Grade IV Life-threatening complication requiring IC/ICU management IVa Single organ dysfunction IVb Multiorgan dysfunction Grade V Death of a patient PS- Higher the score worst the outcome.

  2. Morbidity- Delayed Gastric Empty (DGE) [30days following the pancreaticoduodenectomy]

    Postoperative gastroparesis. Grade A DGE: If the Naso-Gastric Tube (NGT) is needed between the postoperative day (POD) -4 and 7, or if reinserted due to nausea and vomiting after removal by POD 3 and the patient is unable to tolerate a solid diet on POD 7, but starts a solid diet before POD 14. Grade B DGE: If the NGT is needed from POD 8-14, if reinserted after POD 7, or if the patient cannot tolerate unlimited oral intake by POD 14, but is able to resume a solid diet before POD 21. Grade C DGE: When nasogastric intubation cannot be discontinued or has to be reinserted after POD 14, or if the patient is unable to maintain unlimited oral intake by POD 21. PS- Higher the score worst the outcome.

  3. Morbidity- Postoperative pancreatic fistula (POPF) [30days following the pancreaticoduodenectomy]

    A POPF is an abnormal communication between the pancreatic ductal epithelium and another epithelial surface containing pancreas-derived enzyme-rich fluid. Biochemical leak (Grade A): Pancreatic fistula often appears well and requires no intervention. Grade B: Pancreatic fistulas occur in patients who generally appear well, but may require parenteral nutrition or interventional fistula drainage for the fistula to heal. Grade C: Pancreatic fistulas, in which patients appear ill and require parenteral nutrition, interventional drainage, and potentially even re-operation for treatment. PS- Higher the score worst the outcome.

  4. Morbidity- Post pancreatectomy Hemorrhage (PPH) [30days following the pancreaticoduodenectomy]

    Time of onset Early hemorrhage ( 24 h after the end of the index operation) Late hemorrhage ( 24 h after the end of the index operation) Location Intraluminal Extraluminal Severity of Hemorrhage Mild Small or medium volume blood loss (from drains, nasogastric tube, or on ultrasonography, decrease in hemoglobin concentration 3 g/dl) Mild clinical impairment of the patient, no therapeutic consequence, or at most the need for noninvasive treatment with volume resuscitation or blood transfusions (2-3 units packed cells within 24hrs of end of operation or 1-3 units if later than 24hrs after operation) No need for reoperation or interventional angiographic embolization; endoscopic treatment of anastomotic bleeding may occur provided the other conditions apply Severe Large volume blood loss (drop in hemoglobin level by 3g/dl) Clinically significant impairment and need for blood transfusion (3 units packed cells) Need for invasive treatment.

  5. Mortality [30days following the pancreaticoduodenectomy]

    Survival within 30days.

Eligibility Criteria

Criteria

Ages Eligible for Study:
15 Years to 80 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  1. All the cases of elective pancreaticoduodenectomies for malignant pancreatic head disease
Exclusion Criteria:
  1. Incomplete clinicopathological and follow-up data,

  2. Age <15 years and age >80 years

  3. History of antitumor treatments, and

  4. Record of other malignant tumors, (unresectable?)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Chitwan Medical College Teaching Hospital Bharatpur Bagmati Nepal 44207

Sponsors and Collaborators

  • Chitwan Medical College

Investigators

  • Study Chair: Harish Neupane, MBBS, MS, Chitwan Medical Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Gaurav Katwal, Principal Investigator, Chitwan Medical College
ClinicalTrials.gov Identifier:
NCT05506748
Other Study ID Numbers:
  • 078/079-103
First Posted:
Aug 18, 2022
Last Update Posted:
Aug 18, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Aug 18, 2022